(Thursday) 09:00 - 11:00
Open Science is good for business! Open Science’s principles of unrestricted access to data, ideas, results and materials allows multidisciplinary and cross-sector collaborations to transcend intellectual property restrictions in favor of
Open Science is good for business!
Open Science’s principles of unrestricted access to data, ideas, results and materials allows multidisciplinary and cross-sector collaborations to transcend intellectual property restrictions in favor of speed of communication and transparency. The European Union is driving Open Science within many initiatives, such as the Innovative Medicines Initiative (IMI), and has identified Open Science as being a key component of its science policy going forward. Canada has been leading its own Open Science movement, with open science projects such as the SGC, launched in 2004, and open science institutions, such as the Tanenbaum Open Science Initiative at the Montreal Neurological Institute, launched in 2016.
In this panel, representatives from academia, industry and policy-making (Canada and European Union) will address how Open Science can help transform the existing research ecosystem, as well as thrive the creation of robust and measurable economic impacts for the society:
- How open science can drive translation of scientific discoveries into commercial revenue.
- How open science improves reproducibility of scientific research.
- How can government, policy makers, industry and institutions help create social and economic value from open science?
- What are key metrics that should be looked at in terms of economic impact?
- How could Open Science help the global community to better deal with complex challenges that have stumped the scientific and innovation communities?
Ivana Maletić, MEP
Dr. Guy Rouleau,
Director, McGill University Montreal Neurological Institute and Hospital
Wen Hwa Lee, PhD ,
Director, Disease Foundations Network, Strategic Alliances
Director, United Academics
Head of Scientific Foresight Unit, STOA